Eu­ro­pean Com­mis­sion ac­cus­es Te­va of an­ti­com­pet­i­tive scheme as Co­pax­one sales sink

As gener­ic ri­vals cut in­to sales of Te­va Phar­ma­ceu­ti­cals’ block­buster mul­ti­ple scle­ro­sis drug Co­pax­one in North Amer­i­ca, the com­pa­ny has been ac­cused of breach­ing an­titrust rules in an at­tempt to de­lay com­pe­ti­tion across the pond.

The Eu­ro­pean Com­mis­sion an­nounced on Mon­day that it sus­pects Te­va mis­used the patent sys­tem and spread mis­lead­ing in­for­ma­tion about a ri­val to shield Co­pax­one from com­pe­ti­tion in the EU.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER